Navigation Links
CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China
Date:7/21/2014

ROCKVILLE, Md., July 21, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration (CFDA) has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076. 

Ken K. Ren, Ph.D., CASI's Chief Executive Officer, commented, "CFDA's approval of our application represents a significant and exciting milestone for CASI in the execution of our China and global integrated development strategy.  Our Phase II TNBC trial of ENMD-2076 in the U.S. is progressing as planned, and we can now further expand the trial into China with the recruitment of more patients. Data from the China trial can be combined with data being collected in the U.S., and may lead to reaching a clinical inflection point faster. In addition, the China trial will enable us to evaluate the safety and efficacy of ENMD-2076 in the Chinese patient population, providing an opportunity to address unmet medical needs in the country.  Furthermore, data from this trial may be used to support our import drug registration in China in the future."

Dr. Ren continued, "Our development team in Beijing is working closely with our principal investigator and key opinion leaders from leading oncology centers in China in preparation for the trial. We intend to conduct additional trials there as an important component of our China and global integrated development strategy for cost-effective drug development, and to deliver on our mission to bring safer and more effective medicines to patients. We look forward to the continued advancement of ENMD-2076."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.  ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.  Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.  ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.  ENMD-2076 has shown promising activity in Phase I clinical trials in solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia and multiple myeloma.  CASI is completing a Phase II trial of ENMD-2076 in ovarian cancer.  In addition, CASI is conducting a dual-institutional Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma and a Phase II ovarian clear cell carcinomas. ENMD-2076 has received orphan drug designation from the U.S. FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia, and hepatocellular carcinoma.

About CASI Pharmaceuticals, Inc.

CASI is a clinical-stage pharmaceutical company employing a drug-development strategy that leverages resources in both North America and in China to develop therapeutics for the treatment of cancer and other diseases.  Its lead compound is ENMD-2076, a selective angiogenic kinase inhibitor that has completed Phase I studies in solid tumors, multiple myeloma and leukemia.  CASI is conducting Phase II studies with ENMD-2076 in triple-negative breast cancer, advanced/metastatic soft tissue sarcoma and advanced ovarian clear cell carcinomas.  The Company is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D Center in Beijing, China.  Additional information about CASI is available at www.casipharmaceuticals.com and in various filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; the difficulty of executing our business strategy in China; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidate or future candidates; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with our product candidates; risks associated with any early-stage products under development; the risk that results in preclinical models are not necessarily indicative of clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; dependence on third parties; and risks relating to the commercialization, if any, of our proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).  Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition.  We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

COMPANY CONTACT
CASI Pharmaceuticals, Inc. 
240.864.2643 
ir@casipharmaceuticals.com

INVESTOR CONTACT
LHA 
Kim Sutton Golodetz 
212.838.3777 
kgolodetz@lhai.com

Logo - http://photos.prnewswire.com/prnh/20140706/124566


'/>"/>
SOURCE CASI Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... Market research report titled Chronic Inflammation Global Clinical ... a snapshot of the global clinical trials landscape ... clinical trials by Region, Country (G7 & E7), ... point status and reviews top companies involved and ...
(Date:2/11/2016)... Feb. 11, 2016 Stem cells are primitive ... by self-renewal and the capacity to differentiate into mature ... discovery, as the first mouse embryonic stem cells were ... until 1995 that the first culturing of embryonic stem ... were not produced until 2006 As a result of ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... ... Society (INS) states that vein visualization technology should be used to ensure patient ... around the world, the INS Standards mandate the use of vein visualization technology ...
(Date:2/13/2016)... ... 13, 2016 , ... When an Au Pair comes all the way around the ... in for and they are often worried things won’t go well. More often than not, ... year’s Au Pair of the Year winner’s all commented how their Au Pairs have become ...
(Date:2/13/2016)... ... February 13, 2016 , ... DDi ... Management Solution Providers list for its expertise in eClinical Solutions. DDi has built ... serve the technology needs of global clients. DDi provides smarter technology for Clinical ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Mystic Buddha Publishing ... in Blue SKies Buddha, the biography of Rama - Dr. Frederick Lenz. ... story, the love of a Buddhist teacher for teaching and helping others. Valentine’s ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed to introduce ... from U.S. universities who will draw from Siemens’ deep knowledge of product ...
Breaking Medicine News(10 mins):